UP421 maintains graft survival and insulin production at 14 months without immunosuppression

Sana Biotechnology/UP421

NEJM published a letter describing 14-month follow-up data showing that the patient's transplanted HIP-modified islet cells continued to survive and produce insulin without immunosuppression. C-peptide levels remained consistent with early follow-up measurements, and PET-MRI imaging confirmed graft presence at the transplant site.

• 14-month follow-up demonstrates sustained graft survival and continued insulin production
• C-peptide levels at 14 months comparable to first six months of study
• PET-MRI imaging confirmed presence of islet cells at transplant site
• HIP-modified cells evaded immune detection throughout extended follow-up
• Excellent safety profile maintained; represents longest follow-up of allogeneic islet transplant without immunosuppression